Ovid Therapeutics (OVID) Revenue (2020 - 2025)
Ovid Therapeutics (OVID) posted Revenue of $718000.0 for Q4 2025, up 443.94% on a QoQ basis from $132000.0 in Q3 2025, and up 844.74% year-over-year from $76000.0 in Q4 2024.
Ovid Therapeutics (OVID) Revenue (2020 - 2025) Analysis & Trends
Ovid Therapeutics' Revenue history runs 6 years deep, the most recent figure standing at $718000.0 for Q4 2025.
- Quarterly Revenue rose 844.74% year-over-year to $718000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 1199.64% YoY) and the FY2025 annual result came in at $7.3 million, up 1181.27% from the prior year.
- Revenue was $718000.0 for Q4 2025 at Ovid Therapeutics, up from $132000.0 in the prior quarter.
- Across five years, Revenue topped out at $208.4 million in Q1 2021 and bottomed at $11102.0 in Q3 2022.
- A 5-year average of $13.6 million and a median of $137000.0 in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue slumped 99.31% — and 2025, when it soared 3611.24%.
- Ovid Therapeutics' Revenue stood at $208.4 million in 2021, then tumbled by 99.98% to $46280.0 in 2022, then soared by 206.83% to $142000.0 in 2023, then plunged by 46.48% to $76000.0 in 2024, then soared by 844.74% to $718000.0 in 2025.
- Business Quant data shows OVID's Revenue at $718000.0 in Q4 2025, $132000.0 in Q3 2025, and $6.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - | - |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Ovid Therapeutics | 121.66 Mn | -33.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 718,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 6.27 Mn |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 76,000.00 |
| Sep 30, 2024 | 173,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Sep 30, 2023 | 109,000.00 |
| Jun 30, 2023 | 75,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Dec 31, 2022 | 46,280.00 |
| Sep 30, 2022 | 11,102.00 |
| Mar 31, 2022 | 1.45 Mn |
| Mar 31, 2021 | 208.38 Mn |
| Dec 31, 2020 | 5.70 Mn |
| Sep 30, 2020 | 6.91 Mn |